# From molecules to medicine: a systematic review of Gastrodia elata’s bioactive metabolites and therapeutic potential

**Authors:** Xiantai Zhou, Minna Han, Shiyu Yan, Mengyuan Wang, Shengzhou Zu, Shenghui Zhong

PMC · DOI: 10.3389/fphar.2025.1641443 · Frontiers in Pharmacology · 2025-11-07

## TL;DR

This paper reviews the medicinal uses and bioactive compounds of Gastrodia elata, an ancient herb with potential for neurological and anti-aging therapies.

## Contribution

The study systematically reviews GE's traditional uses, bioactive metabolites, and pharmacological mechanisms, highlighting gaps in clinical validation.

## Key findings

- Gastrodin and parishins are key bioactive metabolites with neuroprotective and antioxidant properties.
- Botanical drug interactions improve gastrodin's blood-brain barrier penetration.
- Clinical trials are limited for newer applications like osteoporosis and anti-aging.

## Abstract

The dried tuber of Gastrodia elata (GE), a perennial orchid with a 2,200-year medicinal history documented in the Shennong Bencaojing (200 BCE), remains a cornerstone of traditional Chinese medicine (TCM) and contemporary integrative therapies across Asia. Initially prescribed for neurological disorders (e.g., epilepsy, stroke prophylaxis) and hypertension, modern research has expanded its therapeutic portfolio to include anti-aging, antitumor, and osteoprotective applications. This systematic review synthesizes 1) traditional ethnopharmacological uses, 2) phytochemical profiling of 100+ identified bioactive metabolites (e.g., gastrodin, parishins), and 3) mechanistic insights into their pharmacokinetic behaviors and pharmacodynamic actions. Notably, botanical drug interactions in TCM formulations enhance gastrodin’s blood-brain barrier penetration, elucidating clinical efficacy. While in vitro/vivo studies validate GE’s antioxidant and neuroprotective effects, translational challenges persist: 1) Limited clinical trials on novel indications (e.g., osteoporosis); 2) Unclear structure-activity relationships of minor metabolites; 3) Standardization needs for industrial applications. This work provides an evidence base to guide future research on GE’s diversified therapeutic development.

## Linked entities

- **Chemicals:** gastrodin (PubChem CID 115067), parishins (PubChem CID 177826556)
- **Diseases:** epilepsy (MONDO:0005027), osteoporosis (MONDO:0005298)
- **Species:** Gastrodia elata (taxon 91201)

## Full-text entities

- **Diseases:** osteoporosis (MESH:D010024), epilepsy (MESH:D004827), neurological disorders (MESH:D009461), hypertension (MESH:D006973), stroke (MESH:D020521)
- **Chemicals:** parishins (-), gastrodin (MESH:C045345)
- **Species:** Gastrodia elata (species) [taxon 91201]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12634510/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12634510/full.md

## References

126 references — full list in the complete paper: https://tomesphere.com/paper/PMC12634510/full.md

---
Source: https://tomesphere.com/paper/PMC12634510